News

Advancing medicine, step by step

Learn of and follow our journey to bring about Therapeutic Mitochondria Transfer as a new treatment modality

News News

News & Publications

News

27.09.2021

cellvie featured in Biocentury's Emerging Company Profile

Harvard spinout cellvie is pioneering therapeutic mitochondria transplantation as a way to rescue cell energy metabolism and save cells that would otherwise die. James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when blood supply returns after a period of ischemia.

Read more

News

17.06.2021

CELLVIE CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Award

cellvie AG is proud to announce that CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Entrepreneurship Award among >200 applicants

Read more

News

28.01.2021

CELLVIE closes $5M Seed Round led by Kizoo Technology

Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer

Read more

News

18.11.2020

CELLVIE wins the prestigious MedTech Innovator Value Award

CELLVIE palces among the final 5 contenders for the grant prize of the MedTech Innovator Award and takes home the prestigious MedTech Innovator Value Award

Read more

News

10.07.2020

CELLVIE’s mitochondria treatment has been granted orphan-drug designation from the FDA

cellvie has been granted orphan-drug designation for the use of mitochondria in the prevention of ischemia-reperfusion injury during solid organ transplantation.

Read more
Cellvi Logo Cellvi Logo 2

Get in touch!

Contact